PNC Financial Services Group’s Lexeo Therapeutics LXEO Stock Holding History
Bought
Maintained
Sold
Other funds holding LXEO
PNC Financial Services Group's LXEO Position: Q3 2026 in Review
PNC Financial Services Group increased its Lexeo Therapeutics (LXEO) stake by 144% in Q3 2026, buying an estimated $1.52K and bringing the position to 570 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #4848.
PNC Financial Services Group first reported a position in LXEO in Q3 2025 and has held it in 5 quarters since. The position peaked at $4.84K in Q4 2025. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.
- PNC Financial Services Group held 570 shares of Lexeo Therapeutics worth $1.93K as of Q3 2026.
- PNC Financial Services Group bought 336 Lexeo Therapeutics shares in Q3 2026, an estimated $1.52K.
- Lexeo Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4848 holding.
- PNC Financial Services Group first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 5 quarters since.
- PNC Financial Services Group's Lexeo Therapeutics position peaked at $4.84K in Q4 2025.
- 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.
Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.